Clinical Outcome and Survival in Chronic Myeloid Leukaemia Patients on Second Line Nilotinib Therapy

来源 :The 35th World Congress of the International Society of Hema | 被引量 : 0次 | 上传用户：zhao3785

【摘要】

：

【作者】

：

Ching Soon Teoh Teng Keat Chew Ai Sim Goh

【机构】

：

Haematology Unit,Department of Medicine,Penang General Hospital,Malaysia

【出处】

：

The 35th World Congress of the International Society of Hema

【发表日期】

：

2014年5期

下载到本地 , 更方便阅读

下载此文赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

Objective The introduction of tyrosine kinase inhibitors (TKI) has changed the evolution and prognosis of Chronic Myeloid Leukaemia (CML) worldwide.However,the cost of TKIs is exorbitant and sometimes prohibitive especially in developing countries.Prior to April 2014,CML patients receive Imatinib as first line therapy and Nilotinib is only available as second line therapy in public hospitals in Malaysia mainly through a patient assistance programme.In this study,we report the response rate and overall survival using nilotinib as second line TKI for imatinib resistance or intolerance among CML patients treated in our centre.

其他文献

c-myc Plays Part in Drug Resistance Mediated by Bone Marrow Stromal Cells in Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a malignant disease not sensitive to chemotherapy.The dynamic interaction between AML cells and bone marrow (BM) microenvironment plays a critical role in response of t

会议

FLT3 mutations in acute promyelocytic leukemia patients with extramedullary elapse-case report and l

Objective To evaluate the role of FLT3 gene mutations in acute promyelocytic leukemia (APL)patients with extramedullary relapse.Methods Retrospective analysis of the involved blood and bone marrow sam

会议

The clinical and laboratory research of APL patients with atypical signal modes of PML-RARa detectin

Objective To explore the clinical and laboratory characteristics of of APL patients with atypical FISH signal modes of PML-RARa.Method 52 patients with newly diagnosed APL were detected by DCDF-FISH f

会议

提升預立醫療指示意願書簽署數

[研究背景]坊間從不乏教導我們如何成功、賺進人生第一桶金的書籍，但卻少有課程告知如何面對最後一段人生，加上國人避談死亡議題，因此當疾病或突來意外發生且無法恢復的關鍵時刻，常面臨難以進行醫療決策之窘境.國內推廣安寧護多年，但國人預立醫療指示(以下簡稱ACP)主宰醫療人生之意願表達仍不足，常造成臨床照護困難與家屬間之爭執.[研究目的]1.提升安寧療護認知.2.提升ACP 意願書簽署數.[研究方法方法]

会议

安寧療護預立醫療指示意願書

運用TRM(Team Resource Management)手法降低胸腔內科病房住院病人跌倒發生率

目的美國從1995 年起就參考航空界的CRM(Crew Resource Management)訓練模式來進行不同醫療專業間的團隊訓練課程,以促進團隊合作,並將此手法運用於病人安全的相關議題上.醫策會於2008 年將CRM 引進台灣,將之定名為團隊資源管理(Team Resource Management,TRM),並於醫院間積極推廣.胸腔內科病房的住院病人平均年齡超過65 歲,跌倒是此年齡層住

会议

5-Aza-2'-deoxycytidine and all-trans retinoic acid upregulate levels of p16INK4a and retinoic a

Objective This study was to investigate the effect of 5-Aza-2-deoxycytidine (decitabine;DAC)and all-trans retinoic acid (ATRA) on the expression of p16INK4a(p16) and retinoic acid receptor β(RARβ),as

会议

Chronic lymphocytic leukemia (CLL) with t(14;18)(q32;q21), a possible under-diagnosed and under-reco

Introduction Chronic lymphocytic leukemia (CLL) is the most common form of leukemia in the Western countries (1).The diagnosis of CLL is based on presence of ＞ 5 x109cells/L neoplastic B-cells in the

会议

A new three-way variant t(6;17;15)(p21;q21;q22) in acute promyelocytic leukemian with FLT3-ITD mutat

Acute promyelocytic leukemia (APL) is characterized by the t(15;17)(q22;q21),which results in the fusion of th promyelocytic leukemia (PML) gene at 15q22 with the retinoic acid alpha-receptor(RARa) at

会议

Efficacy and Safety of Bendamustine (B) plus Rituximab(R) For Elderly Patients (p) With Previously U

Introduction A great majority of CLL p are elderly and with same grade of comorbidities.Recently,B as single agent showed superiority in comparison to Chlorambucil,with a good safety profile.Moreover,

会议

Long term follow up of Chronic Myeloid Leukaemia patients on tyrosine kinase inhibitors in Penang, M

Objective Tyrosine kinase inhibitors (TKIs) have significantly improved the prognosis of Chronic myeloid leukaemia (CML) worldwide.Community-based data would be more reflective of the actual outcome a

会议

Clinical Outcome and Survival in Chronic Myeloid Leukaemia Patients on Second Line Nilotinib Therapy

与本文相关的学术论文